Momenta Must Face Clot Drug Antitrust Row, 1st Circ. Told

Law360, New York (November 1, 2016, 3:23 PM EDT) -- Misconduct by Momenta before a standard-setting organization that unknowingly led the group to create a standard for a blood-clot drug that requires the use of a company patent should not allow the generics maker to subsequently receive immunity from antitrust claims, generic rival Amphastar told the First Circuit on Monday.

The District of Massachusetts erred by holding in July that the so-called Noerr-Pennington doctrine allowed Momenta Pharmaceuticals Inc. and co-defendant Sandoz Inc. to escape the antitrust claims brought by Amphastar Pharmaceuticals Inc., which alleged that Momenta...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.